Maximizing Treatment Options for IBD through Drug Repurposing

Title:Maximizing Treatment Options for IBD through Drug Repurposing

Volume: 30

Author(s): Amir Hossein Barjasteh, Abdulridha Mohammed Al-Asady, Hanieh Latifi, Souad Al Okla, Nasser Al-Nazwani, Amir Avan, Majid Khazaei, Mikhail Ryzhikov, Hanieh Nadi Yazdi and Seyed Mahdi Hassanian*

Affiliation:

• Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
• Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract: Chronic inflammation characterizes Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC). Despite modest activity of disease in most UC patients, exacerbations occur, especially in those with severe symptoms, necessitating interventions, like colectomy. Current treatments for IBD, predominantly small molecule therapies, impose significant economic burdens. Drug repurposing offers a cost-effective alternative, leveraging existing drugs for novel therapeutic applications. This approach capitalizes on shared molecular pathways across diseases, accelerating therapeutic discovery while minimizing costs and risks. This article provides an overview of IBD and explores drug repurposing as a promising avenue for more effective and affordable treatments. Through computational and animal studies, potential drug candidates are categorized, offering insights into IBD pathogenesis and treatment strategies.

Cite this article as:

Barjasteh Hossein Amir, Al-Asady Mohammed Abdulridha, Latifi Hanieh, Al Okla Souad, Al-Nazwani Nasser, Avan Amir, Khazaei Majid, Ryzhikov Mikhail, Nadi Yazdi Hanieh and Hassanian Mahdi Seyed*, Maximizing Treatment Options for IBD through Drug Repurposing, Current Pharmaceutical Design 2024; 30 () . https://dx.doi.org/10.2174/0113816128318032240702045822